G.d. Searle & Company

Abbvie Inc.

Pharmacia Corporation

Abbott Laboratories Corporation

Other

Eli Lilly and Company

G.d. Searle LLC

C. D. Searle & Co.

Julie M Miyashiro

Thomas Dale Penning

James W Malecha

Stevan Wakefield Djuric

Ish K Khanna

John Jeffrey Talley

Stephen R Bertenshaw

Richard A Haack

Matthew James Graneto

Paul Waddell Collins

Jeffery S Carter

Donald J Rogier, Jr

Roland S Rogers

Stella S Yu

Stephen Hermann Docter

Keith W Woods

Mark Andrew Russell

Barbara B Chen

Alan Frank Gasiecki

Michael John Clare

Nizal S Chandrakumar

Bipinchandra N Desai

Chi-Dean Liang

Zhi-Fu Tao

Anil Vasudevan

Joseph Gerace Rico

Helen Y Chen

Yunsong Tong

Joe T Collins

Gary A DeCrescenzo

Balekudru Devadas

Andrew J Souers

Thomas Edward Rogers

Sean Colm Turner

Helmut Mack

Peter Gerrard Ruminski

Vincent L Giranda

Jyoti R Patel

Adrian Hobson

Qi Shuai

Irini Akritopoulou-Zanze

Kathy A Sarris

Nicole Teusch

Yi Yu

Chunqiu Lai

Douglas M Kalvin

Biqin C Li

Lu Wang

Dawn M George

Brian D Wakefield

Melissa J Michmerhuizen

Anthony Mastracchio

Steven Lewis Swann, Jr

Vijaya J Gracias

Andrew J Long

Jennifer Ann Van Camp

Eric F Johnson

Peter J Kovar

Richard M Weier

Daniel Paul Becker

Srinivasan Raj Nagarajan

Le Wang

Milan Bruncko

Nan-Horng Lin

Gerard M Sullivan

Francis J Koszyk

Thomas J Sowin

John Gordon Allen

Alan S Florjancic

Laura A Hexamer

Xiangdong Xu

Shashidhar N Rao

Christopher Stanley Galka

Karin Briner

Natalia Pokrovskaia

Maria Angeles Martinez-Grau

Henry Q Zhang

Zhiren Xia

Matthew Robert Reinhard

Richard C Hoying

Renee Huff

Magdalena Przytulinska

Robert Bruce Diebold

Margaretha Bakker

Chunqui Lai

Hwang-fun Lu

Stephen H Doctor

Margaretha H M Bakker

Stella Siu-tzyy Yu

Nigel S Moore

N St John Moore

Mark A, Russell

Monica J Kalman

Robert B Diebold

Thomas Sowin

Disclosed are compound of Formula (Ia), wherein R, R, R, J, Q, X, Y and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (Ia).

Pyridine CDK9 kinase inhibitors

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R, R, Rand m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

5-substituted indazoles as kinase inhibitors

Disclosed are compound of Formula (Ia), wherein R, R, R, R, J, L, T, X, Y, and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).

CDK9 kinase inhibitors

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R, R, R, A, B, and n are defined in the description. The present invention relates also to compositions containing compounds of formula (I) which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

Chemical entities to be used for Wee1 inhibition for the treatment of cancer

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein X, Y, Z, Rand Rare defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

Tricyclic inhibitors of kinases

A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: or a pharmaceutically-acceptable salt thereof.A method of treating inflammation or an inflammation-associated disorder in a subject by administering a therapeutically-effective dose of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, or a pharmaceutically-acceptable salt thereof, to the subject.

4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N&#x2014;R&#x2033;R* where R6 is &#x2014;(CrC3)alkyl-S&#x2014;(C0-C3)alkyl-R10, &#x2014;(C1-C3)alkyl-NR11R12, &#x2014;(CrC3)alkyl-O&#x2014;R13. and other substituents are as defined in the specification. 

[object Object]

Compounds of formula (I) where X, C, and Dare defined herein, are inhibitors of polo-like kinases. The compounds of formula (I) are useful for treatment of diseases of cellular proliferation, such as, for example, cancer.

Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases

Compounds of formula I where X is a bond; Aand A, together with the atoms to which they are attached, is pyrrole; and Aand A, together with the atoms to which they are attached, are benzene; are poly(ADP-ribose)polymerase inhibitors. The compounds of formula I are useful for the treatment of diseases such as cancer.

Pyrroloquinoxalinone inhibitors of poly(ADP-ribose)polymerase

A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II:wherein Ris selected from hydrido, alkyl, haloalkyl, alkoxycaronyl, cyano, cyanoalkyl, carboxyl, aminocaronyl, alkylaminocarbonyl, cycloalklaminocarbonyl, arylaminocarbonyl, carboxyalkylaminocarbonyl, carboxyalkyl, aralkoxycarbonylalkylaminocarbonyl, amioncarbonylalkyl, alkoxycarbonylcyanoalkenyl and hydroxyalkyl; wherein Ris selected from hydrido, alkyl, cyano, hydroxyalkyl, cycloalkyl, alkylsulfonyl and halo; and wherein Ris selected from aralkenyl, aryl, cycloalkyl, cycloalkenyl and heterocyclic; wherein Ris optionally substituted at a substitutable position with one or more radicals selected from halo alkylthio, alkylsulfonyl, cyano, nitro, haloalkyl, alkyl, hydroxyl, alkenyl, hydroxyalkyl, carboxyl, cycloalkyl, alkylamino, dialkylamino, alkoxycarbonyl, aminocarbonyl, alkoxy, haloalkoxy, sulfamyl, heterocyclic and amino; provided Rand Rare not both hydrido; further provided that Ris not carboxyl or methyl when Ris hydrido and when Ris phenyl; further provided that Ris not triazolyl when Ris methyl; further provided that Ris not arakenyl when Ris carboxyl, aminocarbonyl or ethoxycarbonyl; further provided that Ris not phenyl when Ris methyl and Ris carboxyl; and further provided that Ris not unsubstituted thienyl when Ris trifluoromethyl; or a pharmaceutically-acceptable salt thereof.

Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation

The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.

Anilino liver X-receptor modulators

Sulfone liver X-receptor modulators

Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation

Heterocyclic glycyl &bgr;-alanine derivatives

Growing community of inventors

Chicago, IL, United States of America

Julie M Miyashiro